Pharmaceutical market in Russia: State regulation. Latest legislation changes

The declared state reform of the pharmaceutical industry is bound to influence the current state of business.

In the framework of the fifth annual conference dedicated to the pharmaceutical market in Russia, government officials, leading players in business and lawyers will try to answer some of the most significant and important issues of today:

• state control over the pharmaceutical market,
• the most recent changes in legislation,
• new questions and issues that affect business, and much more.

CMS expertise in pharmaceutical market in Russia

Моscow, Swissotel

Program of the 5th annual conference dedicated to the pharmaceutical market in Russia:

9:00 — 9:30 REGISTRATION

9:30 – 12:00 SESSION I. State regulation of the drug market

• Key trends in government regulation of the pharmaceutical market
• Features of state control over the pharmaceutical business in the light of changing legislation
• Presidential decree "On improvement of public health policy": Key comments
• Law "On the inversion of drugs" in the current pharmaceutical market
• Prospects for the pharmaceutical business in Russia in the near future
• "Development Strategy of the Russian Pharmaceutical Industry 2020" — What has changed over the past year?
• The pharmaceutical industry in light of Russia's WTO accession
• Improvement of Russian legislation in the sphere of drugs

12:00 – 12:20 COFFEE BREAK

12:20 – 14:20 SESSION II. Key tax, legal and customs issues in the pharmaceutical market

• State procurement of drugs: adapting to changing market conditions
• Determination of transfer prices in the pharmaceutical market: the Russian Federal Tax Service's position
• The pharmaceutical market in the common space of the Customs Union. What can be expected?
• Regulations on the advertising of drugs. How can companies be sure not to harm the buyer and also "defend" their business?

14:20 – 14:50 COFFEE BREAK

14:50 – 16:50 SESSION III. Russia's WTO accession

Moderator — Galina Balandina, Partner, Head of the Customs Law and Foreign Trade Regulation Practice, Pepeliaev Group

• The pharmaceutical industry in light of Russia's WTO accession
• Regulatory Data Protection (article 18(6) of the Law on the circulation of medicines): instructions for the registering authority, administrative and judicial decisions, and experience abroad
• The anticipated consequences of Russia’s accession to the WTO: economic regulatory measures
• The customs issues in arranging supplies of goods to the countries of the Customs Union and the CIS
• The effect of the WTO on Special Economic Zones in Russia

16:50 – 17:10 COFFEE BREAK

17:10 – 18:30 SESSION IV. Russias Pharmaceutical business today

• Medicinal coverage: the complexity of implementing an insurance program
• Domestic producers on the scene today; upgrading standards within the GMP, the main problems in transitioning to GMP standards
• Development of a healthy competitive environment in today's market
• Organization of a pharmaco-vigilance system in international and Russian pharmaceutical companies: What are the key differences?
• The system of registration of medicines in Russia: the challenges faced by pharmaceutical companies in entering the Russian market

18:30 BUFFETT

INVITED SPEAKERS:

Yelena Maksimkina, head of state regulation of drug treatment, the Health Ministry of the Russian Federation

Timothey Nizhegorodtsev, head of social control and trade, FAS

Mikhail Cherekaev, The Ministry of Economic Development of the Russian Federation

Larisa Popovich, director of the Institute of Health Economics, Higher School of Economics

Viktor Dmitriev, director, ARPM

Maxim Boulba, partner, CMS Russia

Vsevolod Tyupa, senior associate, Lifescience department CMS Russia

Anna McDonald, partner, Co-Head of Russian Life Sciences Practice, Salans

Irina Naumenko, senior associate, Pepeliaev Group

Galina Balandina, partner, head of the customs law and foreign trade regulation practice, Pepeliaev Group

Alexander Kosov, head of practice group for customs and foreign trade regulation, Pepeliaev Group

Valentina Orlova, head of practice IP and trade marks practice, Pepeliaev Group

Yelena Denisova, head of commercial practice, CLIFF

Vladimir Boiko, commercial director, Novatris Consumer Health Russia

Yury Mochalin, corporate affairs director, AstraZeneca

Marina Veldanova, general manager, Ipsen Russia

Payment — 18, 000 Rub + VAT

Regarding conference agenda please contact Irina Marshak

Sponsorship opportunitites — Olga Makarova, Valentina Gvozdeva

Information support — Irina Gavrikova

Registration — Alina Rodionova